Home/ Author / Drew Meredith
    Sort By
  • Newest

  • Newest

  • Oldest

  • Author Name

  • Author Name

  • David Chaplin

  • Drew Meredith

  • Giselle Roux

  • Greg Bright

  • Ishan Dan

  • James Dunn

  • Lachlan Maddock

  • Owen Raszkiewicz

  • All Categories

  • All Categories

  • Opinion

  • News

  • SMSFs

  • Leaders

  • Investing 101

  • TO BE RECATEGORIZED

  • Daily Market Update

  • Investing

  • ASX

  • Global

  • Regulation

  • Markets

  • Asset allocation

  • Economics

  • Retirement

  • Growth

  • Advice

  • ESG

  • ETFs

Drew Meredith

Publishing Editor

Drew is publisher of the Inside Network's mastheads and a principal adviser at Wattle Partners.

Drew Meredith results

Inflation returns, Coles (ASX:COL) sales boom

Inflation returns, Coles (ASX:COL) sales boom, US staggers down 3%, ASX to open over 1% lower The ASX 200 (ASX:XJO) staged a solid comeback after a weak opening, finishing 0.1% higher.  The strength came from the consumer staples and IT sector, up 1.8% and 3.0%, with some new and old names contributing.  On the newer side, was grocery retailer Coles Group (ASX:COL)…

Drew Meredith | 28th Oct 2020 | More
Local investors get ready for a Biden victory

A recent discussion on the likely local impact of the US election between three leading investment experts from ETF Securities (Kanish Chugh, Head of Distribution), Pitcher Partners (David Lane, Director and Senior Adviser) and Evans and Partners (Timothy Rocks, CIO) concluded with consensus advice for Australian investors to maintain their long-term strategy, have an allocation…

ETF Securities | 28th Oct 2020 | More
IPO market review – who delivered in 2020?

Investors ready themselves for Covid-normal And just like that, this crazy year is almost over. As we head into Christmas, Melburnians will breathe a sigh of relief after a marathon lockdown is lifted and the state readies for a “COVID-normal Christmas” – whatever that is. While markets largely shrugged off the COVID effect, it’s been…

Ishan Dan | 28th Oct 2020 | More
Thinking forward: Three ASX biotech stars

And still they keep coming – here’s the fifth instalment of our series on the fascinating ASX cohort of medical device developers. As always, don’t let the impressive sexiness of the technology persuade you on its own that these stocks are headed for the stars. In each of the three cases presented here, previous investors…

James Dunn | 28th Oct 2020 | More
Vanguard – the benevolent fund manager?

Vanguard Group Inc. has drawn many headlines in recent weeks following its decision to “give back” billions of dollars in investment mandates to Australian industry funds. According to Bloomberg reports, the group has been implementing similar strategies in China and throughout the world. The return of (or what some see as a refusal to continue…

Drew Meredith | 28th Oct 2020 | More
  • Ask a guru: What’s an IPO?

    Initial Public Offering 101 If you have been reading any financial media, or even social media, at all throughout 2020, you likely get the feeling that the IPO market has been growing like crazy. This is something my colleague, Ishan Dan, has addressed in his article this week, called IPO market review – who delivered…

    Drew Meredith | 28th Oct 2020 | More
    Our Authors
    Popular